Available via license: CC BY 4.0
Content may be subject to copyright.
EPP0946
Management of diabetes mellitus in patients with severe
mental disorders using new generation hypoglycemic
drugs- A review of the literature
O. Vasiliu
Psychiatry Department, Dr. Carol Davila University Emergency
Central Military Hospital, Bucharest, Romania
doi: 10.1192/j.eurpsy.2023.1226
Introduction: Severe mental disorders (i.e., schizophrenia spec-
trum disorders and bipolar disorders) have been associated with a
high incidence of metabolic dysfunctions, diabetes mellitus
(DM) included. There are multiple factors converging to this
phenomenon, and not all of them are yet known (i.e., a specific
genetic vulnerability, lifestyle factors, adverse events of anti-
psychotics and antidepressants, etc.). Glucagon-like peptide
1 receptor agonists (GLP1RAs), dipeptidyl-peptidase-4-inhibitors
(DPP4Is), and sodium-glucose cotransporter 2 inhibitors
(SGLT2Is) are new hypoglycemic drugs which are generally well
tolerated and associate good glycemic control in clinical trials
(usually in combination with classical antidiabetics).
Objectives: To explore the available evidence supporting the use of
new-generation hypoglycemic drugs (NGHD) in patients with
severe mental disorders with comorbid DM.
Methods: A literature review was performed through the main
electronic databases (PubMed, CINAHL, Clarivate/Web of Science,
and EMBASE) using the search paradigm “schizophrenia spectrum
disorders”OR “bipolar disorders”OR “major depression”AND
“diabetes mellitus”AND “new-generation hypoglycemic agents”
OR “glucagon-like peptide 1 receptor agonists”OR „dipeptidyl-
peptidase-4-inhibitors”OR „sodium-glucose cotransporter
2 inhibitors”. All papers published between January 2000 and
September 2022 were included.
Results: Based on the reviewed papers, GLP1RAs may be useful
(n=20 sources identified) in order to obtain glycemic control in
patients with severe mental disorders receiving antipsychotics;
SGLT2Is added to metformin could be beneficial to the same
population, but data that support their use is extremely limited
(n=4 sources); extremely limited data (n=2) about DPP-4Is do not
allow to formulate any recommendation about this class in patients
with severe mental disorders and associated DM. A number of
ongoing trials have also been identified during this search (n=5),
especially focused on GLP1RAs, which are expected to bring more
information regarding the efficacy and safety of these drugs in this
specific population. Most of the collected data in this review were of
low and moderate quality.
Conclusions: Based on the currently available evidence, GLP1RAs
and SGLT2As may be useful in the management of DM in patients
with severe mental disorders, but more data about their long-term
efficacy and safety is required before making any categorical rec-
ommendation.
Disclosure of Interest: None Declared
EPP0947
The Relationship Between Somatization and
Depression and Anxiety Levels of Parents with Children
Diagnosed with Spina Bifida
P. Ulual
1
*, V. Özer
1
, M. Uyar
2
, I. Alatas
3
, G. Özpınar
2
and O. Guclu
4
1
Psychiatry, Istanbul Basaksehir Cam ve Sakura Sehir Hastanesi;
2
private;
3
neurosurgery, istanbul bilim universitesi and
4
Istanbul
Basaksehir Cam ve Sakura Sehir Hastanesi, Istanbul, Türkiye
*Corresponding author.
doi: 10.1192/j.eurpsy.2023.1227
Introduction: Spina Bifida, a congenital neural tube defect causing
multi-system dysfunction. The birth of a disabled child in the
family inevitably affects the family members, their lives, feelings,
behavior and social life negatively. A lifelong challenge with the
disease may give rise to severe pathologies to the parents or care-
givers; such as somatization disorder which is characterized by
various functional somatic symptoms that can not be explained
by organic pathology. For the DSM-V, the diagnosis of complex
somatic symptom disorder is proposed to replace the current
diagnoses of somatization disorder, undifferentiated somatoform
disorder, hypochondriasis and pain disorder. The proposed diag-
nostic criteria for complex somatic symptom disorder require the
presence of somatic symptoms, together with misattributions,
excessive concern or preoccupation with symptoms and illness
and increased healthcare use.
Objectives: We aimed to find out the relationship between soma-
tization, depression and anxiety levels of parents with children
diagnosed with SB.
Methods: Interview form, the Beck Depression Inventory (BDI),
Beck Anxiety Inventory (BAI), and the SCL-90-R (Psychological
symptoms screening test) were used. 79 individuals were included.
Results: Severely depresssed and anxietic parents show correlating
levels of somatizaton. Depression and anxiety scores were above
normal range. SCL-90-R Test the ratio of general somatization level
compared to other values was found to be 1.72. Parameters above
1 are considered high. This ratio was found to be 100 % in pie charts,
indicating all parents had somatization.
Conclusions: SB is not only physical but also a psychological
burden to the child as well as the parents. Families often find
themselves in despair and feel powerless while giving care to their
child with SB. They have a greater tendency for mood and soma-
tization disorder, long term psychiatric follow-up and more fre-
quent evaluations and interventions should be undertaken.
Disclosure of Interest: None Declared
EPP0948
A comparison about the depression, anxiety, and
despair levels of the parents’of healthy children and
children with Spina bifida disease
P. Ulual
1
*, V. Ozer
1
, G. Özpınar
2
, I. Alataş
3
, R. Çetiner
4
and
O. Güçlü
1
1
Istanbul Basaksehir Cam ve Sakura Sehir Hastanesi;
2
private office;
3
İstanbul Bilim Üniversitesi and
4
İstanbul Eğitim ve Araştırma
Hastanesi, İstanbul, Türkiye
*Corresponding author.
doi: 10.1192/j.eurpsy.2023.1228
European Psychiatry S587
https://doi.org/10.1192/j.eurpsy.2023.1227 Published online by Cambridge University Press